Evidence map›Paper›PMID 37836391›Full record

ArticleNutrients2023

Martin Chrastina, František Dráfi, Katarína Pružinská, Silvester Poništ, Kevine Silihe Kamga, Sasan Khademnematolahi, František Bilka, Peter Novák, Ľudmila Pašková, Katarína Bauerová

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Current pharmaceutical design · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Martin ChrastinaInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine SAS, 841 04 Bratislava, Slovakia.
František DráfiInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine SAS, 841 04 Bratislava, Slovakia.ORCID 0000-0001-9287-5514
Katarína PružinskáInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine SAS, 841 04 Bratislava, Slovakia.
Silvester PoništInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine SAS, 841 04 Bratislava, Slovakia.ORCID 0000-0001-9672-5441
Kevine Silihe KamgaInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine SAS, 841 04 Bratislava, Slovakia.ORCID 0000-0001-9080-7905
Sasan KhademnematolahiInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine SAS, 841 04 Bratislava, Slovakia.
František BilkaFaculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, 832 32 Bratislava, Slovakia.
Peter NovákFaculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, 832 32 Bratislava, Slovakia.
Ľudmila PaškováFaculty of Pharmacy, Comenius University in Bratislava, Odbojárov 10, 832 32 Bratislava, Slovakia.ORCID 0000-0001-8732-7054
Katarína BauerováInstitute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine SAS, 841 04 Bratislava, Slovakia.ORCID 0000-0002-7863-2142
Centre of Experimental Medicine of the Slovak Academy of Sciences · SKComenius University Bratislava · SKUniversité de Yaoundé I · CM

Funding

Scientific grant agency MESRS SR and SAS (VEGA) 1/0429/21Scientific grant agency MESRS SR and SAS (VEGA) 2/0091/23Scientific grant agency MESRS SR and SAS (VEGA) 2/0126/23Scientific grant agency MESRS SR and SAS (VEGA) 2/0136/20The Slovak Research and Development Agency APVV-15-0308
6 · The paper itself

Abstract

Rheumatoid arthritis (RA), an autoimmune disease, is characterized by inflammation that affects not only the liver but also other organs and the musculoskeletal system. The standard therapy for RA is methotrexate (MTX), which has safety limitations. The extract from

Indexed as

Arthritis, ExperimentalArthritis, RheumatoidCrocusAnimalsAnti-Inflammatory AgentsDrug Therapy, CombinationMethotrexateRatsRNA, MessengerAnti-Inflammatory AgentsMethotrexateRNA, Messengerarthritiscombination therapyCRPGGTinterleukinsmethotrexateMMP-9mRNA expressionsaffron

Identifiers

PMID37836391
PMCPMC10574733
OpenAlexW4386996471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.